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(57) ABSTRACT 
This invention provides materials and methods to manipulate 
the plant genome at the level of single plant cells in culture 
resulting in the ability to assign metabolic functionality to 
plant genes involved in the production of biologically active 
molecules and to create a means of product discovery based 
on the biosynthetic capacity of plants. The materials to create 
an activation mutagenesis include incorporation of enhancer 
sequences from a plant viral promoter at random places in the 
plant genome via Agrobacterium mediated DNA transfer 
(T-DNA). The usefulness is that genes in the immediate vicin 
ity of the incorporation were activated which allows for 
immediate screening of the mutageniZed plant cells. Addi 
tionally, the usefulness includes relevant areas of the genome 
were ?anked by the inserted T-DNA which allows recovery of 
this area by standard molecular biology techniques. The 
method includes a procedure for screening large numbers of 
mutageniZed plant cell cultures for activation of a relevant 
gene on the basis of the desired protein product on the basis of 
radioligand binding displacement assay. 
12 Claims, 11 Drawing Sheets 
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METHODS TO IDENTIFY PLANT 
METABOLITES 
CROSS REFERENCE TO RELATED 
APPLICATION 
This application is a divisional ofU.S. application Ser. No. 
10/045,677, ?led Jan. 15, 2002 now US. Pat. No. 6,989,236, 
Which claims bene?t of priority from US. Provisional Appli 
cation Ser. No. 60,267,438, ?led Feb. 9, 2001. 
BACKGROUND OF THE INVENTION 
Plants are sources of drugs and other useful materials. 
These materials are the products of plant metabolism, Which 
is the total collection of biochemical pathWays Within a plant. 
Genes encode the enzymes that function in plant metabolic 
pathWays and regulatory genes, in turn, control the activity of 
metabolic pathWays by directing the expression of entire sets 
of enzyme-encoding genes speci?c to a given pathWay. It 
folloWs that methods to identify any genes that govern the 
production of such plant metabolites are critical to enable the 
manipulation of pathWays for elevating product yield and for 
increasing the diversity of these substances. The present 
invention provides methods to identify, in a relatively e?i 
cient and reliable manner, plant-genetic material required for 
production of metabolites Which Would ordinarily be dif?cult 
to identify. The invention is the realization of the successful 
merging of tWo distinct methodologies: activation-tagging 
mutagenesis and high-throughput screening. The present 
unique combination of these methodologies results in the 
ability to assign metabolic functionality to plant genes 
involved in the production of biologically active molecules 
and to create a means of compound discovery based on the 
genetic capabilities of a plant or group of plants. 
This invention is therefore based on the folloWing technical 
developments: 1) methodology Which enables propagation 
and maintenance of mutagenized “microcallus” material in a 
“library” format in such a Way as to permit large scale screen 
ing; 2) procedures to nondestructively sample the microcal 
lus; 3) methodology to screen the microcallus sample in a 
miniaturized high throughput pharmacological screen. 
Therefore, the invention is in the ?eld of plant molecular 
biology, in particular, genetic methods for production and 
identi?cation of useful compounds. 
Identi?cation of plant genes via activation mutagenesis has 
been used With success previous to the present invention. This 
technique involves incorporation of enhancer sequences from 
a plant viral promoter at random places into the plant genome 
via A grobaclerium mediated T-DNA transfer. When applied 
to single plant cells in culture, the resulting mutants are iden 
ti?ed by positive selection, and the gene(s) in the vicinity of 
the T-DNA insert is cloned. HoWever, elucidation of the 
effects of mutations in regulatory regions, or doWnstream 
effects from a mutagenized gene, are very dif?cult in cases 
Where no positive selection schemes can be employed. Even 
With classical activation mutagenesis methods, Walden et al. 
conclude “this process is involved, labor-intensive and can 
only be effectively carried out With relatively limited numbers 
of segregating individuals.” Walden et al., Methods in Cell 
Biology, 49:455-469 (1995). 
High-throughput screening has also been utilized in the 
pharmaceutical ?eld. 
Citation of the above document is not intended as an admis 
sion that any of the foregoing is pertinent prior art. All state 
ments as to the date or representation as to the contents of 
these documents is based on subjective characterization of 
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information available to the applicant and does not constitute 
any admission as to the accuracy of the dates or contents of 
these documents. 
SUMMARY OF THE INVENTION 
The present invention provides a method for identifying 
plant genetic material Whose actions cause increased produc 
tion of a metabolite or metabolites of interest in plant cells, 
said method comprising causing random integration into the 
plant genome in plant protoplasts of at least one enhancer 
containing T-DNA genetic element harboring sequences to 
enable bacterial replication and selection; groWing said pro 
toplasts to the stage of callus cultures; sampling said callus 
cultures in such a manner as to retain viability of said clonal 
cultures; analyzing said samples to identify the callus cultures 
producing metabolite or metabolites of interest; and isolating 
and identifying the plant genetic material, the action of Which 
has been stimulated by the enhancer-containing T-DNA 
genetic element in the sampled, identi?ed callus cultures. 
Preferred is a method Wherein the plant genetic material, 
Which is identi?ed, is a plant gene Whose action causes a plant 
cell to produce an increased amount of a metabolite or 
metabolites of interest. More preferred is a method Wherein 
the plant genetic material, Which is identi?ed, is a regulatory 
gene. Also preferred is a method Wherein the analysis of 
callus cultures detects the production of metabolites of inter 
est having pharmacological properties. Most preferred is a 
method Wherein said metabolites are detected via at least one 
radioligand displacement assay. 
Methods of the present invention, Which comprises the 
further step of propagating at least one callus, culture produc 
ing said metabolite or metabolites. Most preferred are meth 
ods, Which involve a tobacco plant. 
Most preferred are methods Wherein said enhancer 
sequence is a plant viral enhancer sequence. 
Most preferred are methods Wherein said enhancer 
sequence is delivered to the plant via A grobaclerium Zumefa 
ciens. 
Preferred are methods Wherein said radioligand is a nico 
tinic acetylcholine agonist or a nicotinic acetylcholine 
antagonist. Mo st preferred is the radioligand [3 H] -epibatidine 
or [3 H] -methyllycaconitine. 
The present invention provides a method for identifying 
plant genetic material Whose actions cause increased produc 
tion of a metabolite or metabolites of interest in plant cells, 
said method comprising co-cultivating plant protoplasts With 
Agrobaclerium cells harboring an activation-tagging vector; 
embedding the plant protoplasts in agarose; transferring the 
embedded protoplasts to a larger surface area to alloW further 
groWth; excising individual, clonal calli resulting from said 
groWth; partially macerating individual samples of tissue 
from said calli in multi-Welled microtiter plates to establish a 
sample clonal library; removing supernatant liquid fractions 
from said macerated samples; subjecting said supernatant 
fractions to radioligand displacement assays to determine if 
metabolites in the liquid supernatant displace the radioligand; 
adding groWth medium to remaining tissues in the microtiter 
plate; and isolating and identifying the plant genetic material, 
the action of Which has been stimulated by the action of the 
activation-tagging vector, from the callus cultures Which gen 
erated ligand displacement in the radioligand displacement 
assay. 
The present invention provides methods for detecting a 
metabolite in a plant comprising: causing integration of at 
least one enhancer-containing T-DNA in a plant protoplast; 
groWing said protoplast to the stage of callus culture; sam 
US 7,547,520 B2 
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pling said callus in such a manner so as to retain viability of 
said callus culture; and detecting a metabolite of interest. 
Those methods Wherein said metabolite is detected via at 
least one radioligand displacement assay are preferred. More 
preferred are methods as described Which further comprise 
the step of continuous propagation of at least one stably 
transformed culture. 
In the present invention, methods Wherein the plant is a 
tobacco plant are preferred. Those methods Wherein said 
enhancer sequence is a plant viral enhancer sequence are also 
preferred. Most preferred are those methods, Which utiliZe a 
viral enchancer sequence, delivered via A grobaclerium lume 
faciens. 
When the detection means is a radioligand displacement 
assay, methods Wherein said radioligand is a nicotinic acetyl 
choline agonist or a nicotinic acetylcholine antagonist are 
preferred. In particular, those methods Wherein said radioli 
gand is [3 H] -epibatidine are more preferred. 
Also provided are methods for detecting a metabolite in a 
plant comprising: co-cultivating protoplasts With Agrobacte 
rial cells harboring an activation tagging vector; embedding 
the protoplasts in agarose; transferring protoplasts to a larger 
surface area to alloW further groWth; excising individual calli 
tissue; partially macerating individual calli tissue in a multi 
Welled microtitre plate; establishing a viable callus library; 
removing liquid supernatant; adding groWth medium to tis 
sues remaining in the microtitre plate; and conducting radio 
ligand displacement assay to determine if a metabolite dis 
places the radioligand. 
For the purposes of the present invention, the term “a” or 
“an” entity refers to one or more of that entity; for example, “a 
metabolite” or “a radioligan ” or “an assay” refers to one or 
more of those compounds or at least one compound. As such, 
the terms “a” (or “an”), “one or more” and “at least one” can 
be used interchangeably herein. It is also to be noted that the 
terms “comprising”, “including”, and “having” can be used 
interchangeably. Furthermore, a compound “selected from 
the group consisting of’ refers to one or more of the com 
pounds in the list that folloWs, including mixtures (i.e. com 
binations) of tWo or more of the compounds. According to the 
present invention, an isolated or biologically pure, protein or 
nucleic acid molecule is a compound that has been removed 
from its natural milieu. As such, “isolated” and “biologically 
pure” do not necessarily re?ect the extent to Which the com 
pound has been puri?ed. An isolated compound of the present 
invention can be obtained from its natural source, can be 
produced using molecular biology techniques or can be pro 
duced by chemical synthesis. 
These and other objects of the invention Will be more fully 
understood from the folloWing description of the invention, 
the referenced draWings attached hereto and the claims 
appended hereto. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The present invention Will become more fully understood 
from the detailed description given herein beloW, and the 
accompanying draWing, Which is given by Way of illustration 
only, and thus is not limitative of the present invention. 
FIG. 1 shoWs a protoplast isolation and transformation 
?owchart. 
FIGS. 2A-B. FIG. 2A shoWs a photograph taken through a 
bright ?eld microscope (40>< magni?cation) of freshly iso 
lated protoplasts from tobacco leaves tWo days after isolation. 
At seven days the protoplasts are co-cultivated With A grobac 
Zerium Zumefacians (GV3l0l) to conduct transformation 
resulting in the insertion of the activation-tagging T-DNA. 
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FIG. 2B shoWs a photograph of a cluster of clonal cells after 
several steps of incubation, Washing, antibiotic selection and 
embedding of the multiplied protoplasts. The clusters of 
clonal cells become macroscopic (referred to as “microcalli”) 
as shoWn in the dish in the right of the ?gure. Diameter of the 
petri dish shoWn is 150 mm. 
FIGS. 3A-B. FIG. 3A shoWs a photograph of a plate of 
surface-embedded calli after propagation for approximately 
?ve Weeks (compare to microcalli in FIG. 2). This is an 
example of the type of density used of mutageniZed material 
used for sampling to conduct the pharmacological assay. FIG. 
3B shoWs a photograph of a standard 48-well plate shoWing 
regroWth of the mutageniZed callus tissue after sampling and 
extract preparation Which took place in the same Wells 
approximately three Weeks previously. 
FIG. 4 shoWs a photograph of an “activation-tagging 
mutagenesis” (ATM) library that harbors over 1300 indi 
vidual mutant clones. This illustrates the Workability of estab 
lishing a viable “master” library developed using the methods 
described herein. 
FIGS. 5A-B. FIG. 5A shoWs a photograph of an individual 
screen-positive callus clone that had been physically divided 
and propagated as approximately 20 clonal pieces of separate 
callus tissue. This is used for veri?cation of the pharmaco 
logical phenotype, as each “daughter” individual is expected 
to have the same displacement activity as the “parental” tis 
sue. FIG. 5B shoWs that such pieces are also used for plant 
regeneration from the calli (right half). 
FIG. 6 shoWs a photograph of plants groWing on synthetic 
media in Magenta boxes that had been regenerated from calli 
scored as positive in the screen. 
FIG. 7 shoWs a graph of displacement data of a population 
of mutant (“ATM”) and Wild type (“no ATM”) using 3H-epi 
batidine as the ligand in the pharmacological screen. Non 
mutated samples shoW average displacement of approxi 
mately 3% Whereas the ATM population indicates tWo 
individuals With greater than 30 and 70% displacement activ 
ity, respectively. Note the log scale on the X-axis. These data 
are typical for many thousands of assays run to date. 
FIG. 8 shoWs a summary of activities of positive mutant 
lines and Wild-type controls expressed in terms of “nicotine 
displacement activity” or approximately equivalent to a given 
concentration of nicotine in the displacement assay. Note log 
scale on the Y-axis. The upper clone represents activity 
10,000 times higher than that found in Wild-type calli. This 
line is no. 7309. The line With the loWest activity (and regen 
erated and analyZed at the Whole plant level) is no. 1402. 
FIGS. 9A-D. FIGS. 9A and 9B shoW initial activity char 
acteriZation by displacement activity of line no. 1402 callus 
(See discussion text). The pure anabasine alkaoid and pure 
nicotine alkaloid are used here to standardiZe the system. 
FIGS. 9C and 9D shoW characterization of crude callus 
extracts performed in the same Way as that in A. This differ 
ence in the shape of the pro?les indicates that the activity in 
the 1402 extract is distinct from Wildtype and is most likely a 
compound other than nicotine. 
FIG. 10 shoWs a summary of the molecular characteriza 
tion of cell line 1402. 
DETAILED DESCRIPTION OF THE INVENTION 
The present invention provides a method for identifying 
plant genetic material Whose actions cause increased produc 
tion of a metabolite or metabolites of interest in plant cells, 
said method comprising causing random or directed integra 
tion into the plant genome in plant protoplasts of at least one 
enhancer-containing T-DNA genetic element harboring 
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sequences to enable bacterial replication and selection; groW 
ing said protoplasts to the stage of callus cultures; sampling 
said callus cultures in such a manner as to retain viability of 
said clonal cultures; analyzing said samples to identify the 
callus cultures producing metabolite or metabolites of inter 
est; and isolating and identifying the plant genetic material, 
the action of Which has been stimulated by the enhancer 
containing T-DNA genetic element in the sampled, identi?ed 
callus cultures. 
Preferred is a method Wherein the plant genetic material, 
Which is identi?ed, is a plant gene Whose action causes a plant 
cell to produce an increased amount of a metabolite or 
metabolites of interest. More preferred is a method Wherein 
the plant genetic material, Which is identi?ed, is a regulatory 
gene. Also preferred is a method Wherein the analysis of 
callus cultures detects the production of metabolites of inter 
est having pharmacological properties. Most preferred is a 
method Wherein said metabolites are detected via at least one 
radioligand displacement assay. 
Methods of the present invention may also comprise the 
further step of propagating at least one callus culture produc 
ing said metabolite or metabolites. Most preferred are meth 
ods, Which involve a tobacco plant and Wherein said enhancer 
sequence is a plant viral enhancer sequence. 
Most preferred are methods Wherein said enhancer 
sequence is delivered to the plant via A grobaclerium Zumefa 
ciens. 
Preferred are methods Wherein said radioligand is a nico 
tinic acetylcholine agonist or a nicotinic acetylcholine 
antagonist. Mo st preferred is the radioligand [3 H] -epibatidine 
or [3H]-methyllycaconitine. 
In a preferred embodiment, the present invention provides 
a method for identifying plant genetic material Whose actions 
cause increased production of a metabolite or metabolites of 
interest in plant cells, said method comprising co-cultivating 
plant protoplasts With A grobaclerium cells harboring an acti 
vation-tagging vector; embedding the plant protoplasts in 
agarose; transferring the embedded protoplasts to a larger 
surface area to alloW further groWth; excising individual, 
clonal calli resulting from said groWth; partially macerating 
individual samples of tissue from said calli in multi-Welled 
microtiter plates to establish a sample clonal library; remov 
ing supernatant liquid fractions from said macerated samples; 
subjecting said supernatant fractions to radioligand displace 
ment assays to determine if metabolites in the liquid super 
natant displace the radioligand; adding groWth medium to 
remaining tissues in the microtiter plate; and isolating and 
identifying the plant genetic material, the action of Which has 
been stimulated by the action of the activation-tagging vector, 
from the callus cultures Which generated ligand displacement 
in the radioligand displacement assay. 
The present invention provides methods for detecting a 
metabolite in a plant comprising: causing integration of at 
least one enhancer-containing T-DNA in a plant protoplast; 
groWing said protoplast to the stage of callus culture; sam 
pling said callus in such a manner so as to retain viability of 
said callus culture; and detecting a metabolite of interest in 
the event that the metabolite of interest is present. Those 
methods Wherein said metabolite is detected via at least one 
radioligand displacement assay are preferred. More preferred 
are methods as described Which further comprise the step of 
propagating at least one daughter culture. 
In the present invention, methods Wherein the plant is a 
tobacco plant are preferred. Those methods Wherein said 
enhancer sequence is a plant viral enhancer sequence are also 
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preferred. Most preferred are those methods, Which utiliZe a 
viral enhancer sequence, delivered via A grobaclerium lume 
faciens. 
When the detection means is a radioligand displacement 
assay, methods Wherein said radioligand is a nicotinic acetyl 
choline agonist or a nicotinic acetylcholine antagonist are 
preferred. In particular, those methods Wherein said radioli 
gand is [3 H] -epibatidine are more preferred. 
Also provided are methods for detecting a metabolite in a 
plant comprising: co-cultivation of protoplasts WithAgrobac 
terial cells harboring an activation-tagging vector; embed 
ding the protoplasts in agarose; transferring protoplasts to a 
larger surface area to alloW further groWth; excising indi 
vidual calli tissue; partially macerating individual calli tissue 
in multi-Welled microtitre plate; removing liquid supernatant; 
conducting radioligand displacement assay to determine if a 
metabolite displaces the radioligand; and adding groWth 
medium to tissues remaining in the microtitre plate. 
Other methods of transformation include: biolistic bom 
bardment and polyethylene glycol-mediated DNA uptake. 
Plant cells may also be transformed With other sequences 
With the ability to cause the activation of genes such as 
enhancer sequences from different promoters and sequences 
encoding transcription factors that can function to activate 
gene expression or from the introduction of populations of 
genes in order to determine their impact on metabolite pro 
duction. 
The supernatant may be assayed for products of secondary 
metabolism With radiolabelled ligand binding assays. Pre 
ferred ligands are acetylcholine agonists and antagonists. 
More preferred are 3H-methyllycaconitine, 3H-spermidine. 
Most preferred is 3H-epibatidine. 
Preferred enhancer sequences include tissue-speci?c pro 
moter enhancers and temporal-speci?c promoter enhancers. 
Most preferred is a constitutive plant viral promoter active in 
plant cells and undifferentiated callus tissue. 
Enhancer sequences may be contained Within vectors 
enabling the transfer of said sequences into the plant genome. 
The term “antagonist” is intended to refer to that Which is 
understood in the art. In general, the term refers to a sub stance 
that interferes With receptor function. Antagonists are of tWo 
types: competitive and non-competitive. A competitive 
antagonist (or competitive blocker) competes With the natu 
rally occurring ligand for the same binding site. In the case of 
acetylcholine, an example of such an antagonist is bungaro 
toxin. A non-competitive antagonist or blocker inactivates the 
functioning of the receptor by binding to a site other than the 
acetylcholine-binding site. 
Speci?cally, the radiolabeled ligand may bind nicotinic 
acetylcholine receptors. The preferred radiolabeled ligand is 
[3H]-epibatidine, a nicotinic cholinergic receptor agonist. 
Cholinergic receptors play an important role in the function 
ing of muscles, organs and generally in the central nervous 
system. There are also complex interactions betWeen cholin 
ergic receptors and the function of receptors of other neu 
rotransmitters such as dopamine, serotonin and catechola 
mines. 
Acetylcholine (ACh) serves as the neurotransmitter at all 
autonomic ganglia, at the postganglionic parasympathetic 
nerve endings, and at the postganglionic sympathetic nerve 
endings innervating the eccrine sWeat glands. Different 
receptors for ACh exist on the postganglionic neurons Within 
the autonomic ganglia and at the postjunctional autonomic 
effector sites. Those Within the autonomic ganglia and adre 
nal medulla are stimulated predominantly by nicotine and are 
knoWn as nicotinic receptors. Those on autonomic effector 
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cells are stimulated primarily by the alkaloid muscarine and 
are known as muscarinic receptors. 
The nicotinic receptors of autonomic ganglia and skeletal 
muscle are not homogenous because they can be blocked by 
different antagonists. For example, d-tubocurarine effec 
tively blocks nicotinic response in skeletal muscle, Whereas 
hexamethonium and mecamylamine are more effective in 
blocking nicotinic responses in autonomic ganglia. The nico 
tinic cholinergic receptors are named the NM and NN recep 
tors, respectively. 
Acetylcholine receptors at any or all of the above men 
tioned locations may be assayed by radiolabeled ligand bind 
ing assays in the present invention. 
EXAMPLES 
The folloWing examples illustrate the present invention 
Without, hoWever, limiting it. It is to be noted that the 
Examples include a number of molecular biology, microbi 
ology and biochemistry techniques considered to be knoWn to 
those skilled in the art. Disclosure of such techniques can be 
found, for example, in Sambrook et al., ibid., and related 
references. 
Example 1 
Leaf Protoplast Preparation 
GroWing Conditions: Tobacco plants (Nicoliana Zabacum 
SR1) Were groWn in sterile culture on MS media (One liter 
contains: 4.3 g MS basal salt mixture (Sigma), 0.5 g MES 
(2-[N-Morpholino]ethanesulfonic acid) (Sigma) for buffer 
ing, 10 g sucrose. The pH Was adjusted to 5.8 With KOH. 
Media Was solidi?ed by adding Phytagel (Sigma) to 0.2%. 
Sterilization Was by autoclaving in Magenta boxes. Magenta 
boxes contained lids With a vent provided by a 2 cm diameter 
hole covered With a single 0.45 pm pore siZe ?lter disc (Type 
HA, Millipore) and tWo pieces of “Micropore” surgical tape 
(3M). Plants groWn for four to ?ve Weeks at 240 C. under 
approximately 1 10 umol m_2s_l light intensity Were used as a 
source of leaf material. 
Leaf Preparation Procedure: Under sterile conditions, leaf 
tissue Was removed from the plants and cut into approxi 
mately 1 cm2 pieces using a sharp scalpel or raZor blade. 
Approximately 5 g of leaf material Was added to 20 ml ?lter 
steriliZed enZyme solution (1.5% cellulase, 0.5% pectinase, 
(Sigma)) in K3 plant culture media. K3 media contains 10 ml 
per liter of the folloWing stock solutions: NaH2PO4 (3 g/200 
ml); CaCl2 (18 g/200 ml); (NH4)2SO4 (2.7 g/200 ml); MgSO4 
(5 g/200 ml); KNO3, (5 g/200 ml); NH4NO3 (2.7 g/200 ml). 
Added directly to one liter of K3 media Was inositol, 100 mg; 
xylose, 250 mg; and MES buffer, 2.0 g. In addition, K3 media 
also contained 10 ml per liter of a micronutrients solution and 
1.0 ml per liter of a vitamin solution. The micronutrient 
solution Was prepared by dissolving the folloWing into one 
liter H2O: H3BO3, 6.2 g; MnSO4'4H2O, 22.3 g; 
ZnSO4.7H2O, 10.6 g; Kl, 0.88 g; NaMoO4'2H2O, 0.25 g; 
CuSO4'5H2O, 0.025 g; and CoCl2'6H2O, 0.025 g. The vita 
min stock solution Was made by dissolving the folloWing in 
200 ml H2O: glycine, 400 mg; nicotinic acid, 400 mg; pyri 
doxin-HCl, 400 mg; thiamin-HCl, 20 mg. 5.0 ml of an Fe 
EDTA solution Was added from a stock, prepared by dissolv 
ing 5.57 g FeSO4'7H2O and 7.45 g NaZEDTA. To prepare K3 
containing 0.4M sucrose, 136.92 g sucrose Was added. 0.1M 
sucrose K3 media contains 34.23 g sucrose. 
Protoplast Isolation: Leaves Were digested overnight (no 
more than 19 h) by incubation at 260 C. in the dark. The 
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folloWing day, 250 ml beakers Were mixed for 10 min on an 
orbital shaker (approximately 40 rpm), and the solution Was 
passed through a 105 um mesh sieve by pouring through a 
?ltration apparatus. This Was divided into 17><100 mm sterile 
plastic centrifuge tubes, Which Were then centrifuged at 2000 
rpm in a sWinging bucket rotor for 6 minutes at room tem 
perature. Following the centrifugation, protoplasts, Which 
?oat at the top of the media in the centrifuge tube, Were 
removed from the pelleted debris by aspirating the loWer 
contents of the tube. Protoplasts Were Washed by addition of 
0.4M K3 media and recentrifuged. The protoplasts from these 
Were pooled into one or tWo single screW cap sterile tubes. 
After adjusting protoplast cell density, cells Were further 
incubated as 10 ml cultures in standard (60 mm) petri dishes. 
Dishes Were Wrapped With para?lm for incubation at 260 C. in 
the dark for tWo days. 
Example 2 
Activation-Tagging Mutagenesis: Protoplast 
Transformation 
Materials: Agrobaclerium Zumefaciens strain GV3101, is 
described in KoncZ and Schell, Mol Gen Genet 204:383-396. 
1 986, Which is incorporated herein by reference in its entirety. 
The plasmid pPCVlCEn4HPT containing the T-DNA tag Was 
used. It Was made as described in FritZe and Walden, Methods 
in Molecular Biology 44:281-294. 1995 and in Walden, FritZe 
and Harling, Methods in Cell Biology 49:455-469. 1995, 
Which references are incorporated by reference herein in their 
entirety. pPCVlCEn4HPT is derived from the pPCV vector 
(KoncZ and Schell, Mol Gen. Genet 213:285-290, 1986) in 
Which the T-DNA contains four tandemly repeated enhancer 
elements derived from the 35S RNA promoter of the Cauli 
?oWer mosaic virus, a hygromycin resistance marker for pro 
toplast and plant selection and an E. coli plasmid sequence 
that contains an E. coli origin of replication and an ampicillin 
resistance gene. 
Procedure: Transformation With the activator T-DNA tag 
Was performed by co-cultivation With A grobaclerium lume 
faciens harboring the T-DNA tagging element (strain 
GV3101, plasmid pPCVlCEn4HPT). Freshly groWn bacte 
rial cells Were added directly to six to eight day-old protoplast 
cultures in a ratio of 100:1 bacteria to protoplast cells. Co 
cultivation Was conducted at 260 C. in the dark for 48 hr. At 
the end of the incubation period, protoplasts Were Washed 
three times in W5 media by centrifugation in a sWing-out 
rotor at room temperature. W5 media contained NaCl, 9.0 
g/liter; CaCl2'2H2O, 18.38 g/liter; KCl, 0.373 g/liter; and 
glucose, 0.90 g/liter. The pH Was adjusted to 5.6-6.0, With 
HCl. The medium Was steriliZed by autoclavation. Proto 
plasts Were then resuspended in 0.4M K3 media to produce a 
?nal concentration of 106 protoplasts per ml. One ml of 
protoplast suspension Was transferred to a standard (100 mm) 
petri dish and cultured in a ?nal volume of 10 ml of 0.4 M K3 
media containing antibiotic selection against A grobaclerium 
cells (cefotaxime 500 ug/ml) as Well as the presence of hor 
mones to maintain cells in a dedifferentiated state (auxin 
(NAA) 1.0 ug/ml and cytokinin (kinetin 0.2 ug/ml). Hygro 
mycin (15 ug/ml) Was also added to the incubation media to 
select for the protoplasts transformed With the activation 
tagging vector. 
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Example 3 
Propagation of Protoplasts and Calli 
Culturing of Protoplasts: Transformed cells Were embed 
ded in 0.3% loW gelling temperature agarose in 100 mm petri 
dishes. K4 media Was then added to the petri dishes contain 
ing the soft agarose embedded microcalli. Following proto 
plast embedding, the K4 media Was reduced in osmolarity in 
0.1M increments, (starting at 0.4M sucrose, ~580 mOsm) on 
a Weekly basis by changing the liquid phase media over the 
soft agarose embedded cells. “K4” media contains 10 ml per 
liter of the folloWing stock solutions: NaHZPO4 (3 g/ 200 ml); 
CaCl2 (18 g/200 ml); KCl (58.8 g/200 ml); glutamine (17.54 
g/200 ml); asparagine (5.32 g/200 ml); arginine (3.52 g/200 
ml); (NH4)2SO4 (2.7 g/200 ml); MgSO4 (5 g/200 ml). Added 
directly to one liter of K4 media is inositol, 100 mg; xylose, 
250 mg, and MES buffer, 2.0 g. In addition, K4 media also 
contains 10 ml per liter of a micronutrients solution and 1.0 
ml per liter of a vitamin solution With the same composition as 
that used for the K3 media as Well as 5.0 ml per liter of a 
Fe-EDTA solution and sucrose to 0.4 or 0.1M. 
Transfer to Larger Areas for Additional GroWth: Once 
microcalli Were established (usually four to ?ve Weeks), they 
Were released from the agarose by gentle maceration and 
dilution. Microcalli Were further cultured by “surface plat 
ing” the transformed tissue onto 0.1M K4 media solidi?ed 
With 0.8% agar in 150 mm dishes. The released microcalli 
Were “re-embedded” in loW gelling-temperature agarose and 
plated to the surface of solidi?ed K4 media agar plates. This 
results in a 2 mm thick monolayer of embedded microcalli on 
the plate such that further groWth forms an upWard protrusion 
of the calli large enough for physical sampling. Dilutions 
Were empirically made to adjust the number of individual 
microcalli on each dish to densities suf?cient to enable con 
tinued groWth of the microcalli up to the stage of sampling. 
Example 4 
Nondestructive Sampling and Library Establishment 
The three steps of sampling, establishment of a viable 
Working library and extract preparation of surface-groWn 
macrocalli are combined into a single process to maximiZe 
throughput. Surface-embedded microcalli groWn to siZes 
ranging from approximately 0.5 cm to 1.5 cm (“macrocalli”) 
are deemed su?icient for sampling and establishing the mas 
ter library. Under sterile conditions, petri dishes containing 
the surface-groWn macrocalli are opened and macrocalli are 
individually sampled using ring forceps (4.8 mm inner ring 
diameter, Fine Science Tools, Inc. Foster City, Calif.). This 
ring siZe enables a section of tissue Weighing approximately 
50 mg to be sampled. The removed tissue section is placed 
into the numbered Well of a 48-Well microtiter plate contain 
ing 0.4 ml fresh K4 media including required groWth regula 
tors. Once the 48-Well dishes are loaded, a maceration pestle, 
custom made of DelrinTM plastic (12 cm in length><1-cm dia.) 
With the maceration end machined to a semi-circle (one-half 
of the 1-cm circular end) is used to partially macerate the 
tissue in the Well of the plate. Partial maceration is conducted 
to break open a su?icient proportion of the cells Within the 50 
mg piece of callus tissue to release the cellular contents for 
analysis and to maintain an amount of this tissue (generally 
about 1/3 of each callus section) in the Well to enable continued 
groWth and recovery. Because the 3H-epibatidine displace 
ment assay (beloW) can be used With K4 callus groWth media, 
recovery and groWth of the microcalli Within the Wells is 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
10 
virtually 100%. Additional media is added to each Well to 
increase the volume to 1.0 ml. 0.65 ml of the 1.0 ml volume of 
cellular ?uid resulting from the partial callus maceration in 
each Well is removed and transferred to standard 1.5 ml 
micro-centrifuge tubes. After sealing the lids of the 48-Well 
dishes With surgical tape (3M), they are placed in a lighted 26° 
C. incubator for recovery and groWth. The groWing calli 
Within the 48-Well dishes establishes the Working library. 
Example 5 
Extract Preparation 
Micro-centrifuge tubes containing 0.65 ml of cell tissue 
?uid and K4 groWth media are centrifuged at 13,000 rpm for 
ten minutes at room temperature. The supernatant is removed 
and placed into clean micro-centrifuge tubes and stored at 
—80° C. until used for displacement assays. 
Example 6 
[3H]-epibatidine Screening 
Tissue Preparation: Crude membrane preparations from 
brains of male adult Sprague-DaWley rats Were prepared from 
methods modi?ed after Houghtling R A, Davila-Garcia M l, 
Kellar K J, Mol Pharmacol 48(2):280-7, 1995, Which refer 
ence is incorporated by reference herein in its entirety. Fol 
loWing sacri?ce by rapid decapitation, the frontal cortex and 
hippocampus Were rapidly dissected and homogeniZed in 
ice-cold sucrose buffer (0.32 M sucrose, 1 mM EDTA, 0.1 
mM phenylmethylsulfonyl ?uoride, 0.01% Wt/vol sodium 
aZide; pH adjusted to 7.4) using a polytron tissue homog 
eniZer. The homogenate Was centrifuged at 1000><g at 4° C. 
for 10 min. The pellet Was resuspended in sucrose buffer and 
the centrifugation repeated. The supernatant fractions Were 
combined and the P2 membranes recovered as a pellet after 
centrifugation 15000><g at 4° C. for 20 min. The pellet Was 
Washed tWice by resuspension in phosphate buffer (same as 
above, except 50 mM phosphate substituted for sucrose) and 
centrifuged at 15000><g at 4° C. for 20 min. The ?nal pellet 
Was resuspended in phosphate buffer. Protein Was determined 
by the BCA Protein Assay kit from Pierce, Rockford Ill. 
Aliquots Were stored at —80° C. until use. 
Preparation of membrane homogenates: Fresh tissue (bo 
vine brain) Was procured immediately after euthanasia by 
exsanguination. Alternatively, standards and replication of 
results Were con?rmed in male Sprague-DaWley rat cerebrum 
homogenates derived from animals sacri?ced by rapid 
decapitation. The preparation of these membranes Was iden 
tical to bovine homogenates. Frontal cortex Was blocked, then 
placed in ice-cold HEPES buffer (50 mM) for 10 min. Tissue 
Was Weighed, and 4 ml of “incubation” buffer Was added. 
Tissue Was homogeniZed in a 30 ml vol. glass hand-held 
tissue homogeniZer With a te?on pestle. The crude homoge 
nate Was Washed 3 times by centrifugation at 35,000><G for 20 
min at 4° C. After each centrifugation, the homogenate Was 
re-suspended in fresh, cold buffer. FolloWing ?nal Washing, 1 
ml aliquots Were snap-froZen in liquid nitrogen and stored in 
a —20° C. freeZer until use. Prior to use in binding assays, total 
protein concentration Was determined using a modi?ed 
LoWry method (Sigma Kit) for membrane bound proteins. 
Protein concentration effects and protein loss Were investi 
gated by preparing aliquots of knoWn dilutions of membrane 
protein suspension into Wells, ?ltering, and measuring the 
protein concentration remaining on the plate ?lters via the 
LoWry method. 
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Competition binding: To reduce binding of radiolabel to 
?lters, 0.1% BSA Was added to the assay buffer. Membranes 
Were diluted With buffer to yield a ?nal protein concentration 
of 600 pg/Well (2 mg/ml). Membranes Were added to the 
Wells of a 96-Well microtiter plate and incubated at room 
temperature With 10 nM [3H]-MLA, and unlabelled ligand or 
unknown samples (100 pl each). Incubation Was halted after 
2 hr by the addition of ice-cold buffer. The contents of the 
microtiter plate Were harvested onto a 96 Well ?lterplate using 
a plate harvester (Packard, Inc). Filters Were Washed 5>< With 
ice cold buffer and the ?lterplate dried overnight. Scintillation 
cocktail Was then added to the ?lters and the entire plate 
counted using a TopCountTM 96-Well plate scintillation 
counter, Packard Instruments, Meriden Conn. 
Procedures for 3H-epibatidine binding in 96-Well ?lter 
plates: All procedures Were performed at room temperature, 
unless noted. Assays Were performed in standard (350 pl Well 
volume) 96 Well microtiter plates. Nicotine or a sample com 
petitor Was added to 8 Wells at a time using an 8-channel 
multipipettor. Crude sample extracts Were solubiliZed using 
1N HCl, if necessary. UnknoWn samples Were diluted With 
incubation buffer (50 mM Tris-HCl, 120 mM NaCl, 5 mM 
KCl, 1 nM MgCl2, 2 mM CaCl2, pH adjusted to 7.4) 1:10. 
This dilution alloWs an approximate Weight:volume ratio of 
100 mg/ml of unknoWn sample per Well. 100 pl of a competi 
tor Was added to each respective Well. Non speci?c binding 
for epibatidine Was determined using 10 mM nicotine com 
petition. Membrane homogenates Were thaWed on ice and 
diluted With incubation buffer for ?nal protein concentration 
of each Well equal to 4 mg/ml. Membrane homogenate prepa 
ration Was added to 8 Wells at a time, using 8-channel pipettor. 
A competitor Was incubated Within Wells for 1 hr. at room 
temp. Following incubation of competitor, 3H-epibatidine 
(New England Nuclear) Was added to each Well and incubated 
for 2 hr. FolloWing incubation, the plate Was harvested onto a 
96 Well GF/B ?lter plate using a Packard 96 Well harvester, 
and rapidly Washed 3x With 350 pl 50 mM Tris-HCl buffer 
(pH:7.4). The plate Was then alloWed to dry overnight, then 
30 pl MicroScint20TM Was added to each Well before counting 
With a Packard TopcountTM 96-Well plate scintillation 
counter. Each Well Was counted for 2 min. Speci?c binding in 
the presence of competitor Was converted to percentage of 
total speci?c binding of 3H-epibatidine alone. Signi?cant 
differences Were calculated from CPM averages using Stu 
dent’s 2 tailed t tests. 
Example 7 
Results 
Screening of Activation-Tagged Microcalli: 4400 activa 
tion tagged microcalli Were screened in a six month period. 
This Was a 75% increase in ef?ciency over previous method 
ologies. 
Identi?cation of Microcalli With Signi?cant Alkaloid-Dis 
placing Activity: TWo stable cell lines Were identi?ed that 
shoWed signi?cant alkaloid-displacing activity. One of these, 
1402, Was examined at the Whole plant level and shoWed a 
7.5-fold increase in the level of displacement activity over the 
Wild type in extracts prepared from leaf punches from non 
transformed plants. The second identi?ed isolate, 5094, 
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shoWed displacement activity in callus tissue extracts equiva 
lent to alkaloid levels of several orders of magnitude over the 
Wild-type calli. 
Example 8 
Isolation and Replication of Activated Genes 
Isolation: Molecular genetic techniques are conducted 
using standard methodologies. The analytical sequence is 
determined by isolating the plant genomic DNA activated by 
the T-DNA insert through Southern hybridiZation analysis, 
folloWed by polymerase chain reaction (PCR) to establish the 
insert number and structure. Cloning of the T-DNA along 
With ?anking genomic plant DNA Will depend on the struc 
ture of the insert, ?rst utiliZing plasmid rescue for single site 
T-DNA insertions. If there are multiple inserts, then genomic 
libraries Will be prepared and screens conducted on these to 
obtain genomic clones linked to the T-DNA that contain dif 
ferent plant genomic DNA sequences. Resulting clones can 
be sorted ?rst by Southern analysis and then functionally by 
reintroduction into Wild-type protoplasts and scoring micro 
calli for the original phenotype. If necessary, subclones of the 
recovered ?anking plant DNA can be prepared and tested for 
activity by fusing various fragments doWnstream of the 35S 
promoter of the Cauli?oWer mosaic virus, introducing these 
back into protoplasts and scoring these cells for the pheno 
type. Once the putative activated genomic DNA is identi?ed, 
it is used as a probe to screen cDNA libraries of tobacco. In 
addition, functional analysis to determine nicotinic alkaloid 
pathWay upregulation can be performed by reverse transcrip 
tion PCR using oligonucleotide primer speci?c to the pmt 
gene of tobacco. This provides early molecular evidence if the 
alkaloid pathWay Was induced in callus tissue, for example. 
Example 9 
We have prepared extracts from about 8000 clonal cultures 
and have screened these for [3H]epibatidine-displacing activ 
ity. Approximately 12 of these produced activity that met the 
criteria of being “positive” in the ?rst screen. Of these, only 
three have met the criteria that daughter cultures should con 
tinue to overproduce activity in the screen through several 
cycles of groWth and separation. The extent of the increase in 
activity varies markedly betWeen these three clones. Thus, the 
?rst clone isolated (#1402) producing a compound or com 
pounds With a biological activity in the screen equivalent to a 
concentration of nicotine an order of magnitude higher than 
that produced by Wild-type cultures (see FIG. 8). A very 
recent clone (#7309) is producing activity about 10,000>< that 
of Wild-type Whereas the other clone (#5094) is intermediate 
betWeen these (FIG. 8). Because We isolated #1402 ?rst We 
have spent most time characterizing this clone, and the spe 
ci?c ?ndings Will be described beloW. 
The results shoW that ATM can be used to create a large 
library of mutant clonal cultures (see FIG. 4) that can be 
maintained by a small number of research Workers. We have 
also shoWn that clones in this library can be repeatedly 
sampled and separated Without destroying the individual cul 
tures. Extracts from these cultures can therefore be sampled 
and screened serially to evaluate Whether the genetically pro 
duced chemical phenotype is stable. We have also shoWn that 
it is possible to adapt pharmacological HTS techniques to 
evaluation of a clonal library produced by ATM, and that the 
amplitude of changes in secondary metabolites from Wild 
type or other control cultures that are produced by ATM can 
be detected by this HTS. We are thus able to combine ATM 
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and HTSithe ?rst requirement for proof of the Natural Prod 
ucts Genomics concept. Our results using this combination of 
techniques shoW that a small number of clones (currently 
around 1 in 2,700 mutants) can be regarded as stable alter 
ations in genes that increase the synthesis of products With a 
biological activity similar to nicotine. These products may be 
nicotine itself, or some other chemical With activity in the 
screen, at this stage We do not knoW. Similarly, the genes that 
have been activated may have an impact on the nicotine 
metabolic pathWay, or be completely unrelated to this. All We 
knoW is that they increase the production of natural com 
pounds With potentially useful biological activity that is simi 
lar to that of nicotine. In fact, We may Well be underestimating 
the numbers of clones that have this type of value. About 75% 
of the clones that give a positive result in the ?rst screen 
eventually fail, sometimes after several generations of posi 
tive daughter cultures. Some cultures even recover activity 
after producing negative data for a While. In some cases, this 
may indicate that We have activated a gene that regulates the 
production of the natural product very indirectly, and that its 
effects can be over-ridden by other genes that may be acti 
vated by environmental or developmental factors beyond our 
control. HoWever, such genes might still be useful as a means 
of regulating synthesis of the natural product. We have been 
deliberately conservative in our criteria to avoid the criticisms 
previously associated With unstable somatic mutations in 
plant cell culture. Considered together We believe that our 
results demonstrate that ATM and HTS have the potential to 
act as a discovery platform for those genes that regulate the 
synthesis of natural products in plants. As our characteriza 
tion of clone 1402 has shoWn (see beloW) this Natural Prod 
ucts Genomics approach has utility as a drug discovery plat 
form technology. 
Clone 1402 has noW consistently over-produced activity in 
the epibatidine displacement screen for about 18 months. 
This has been in various incarnations of the original clonal 
material that originated from a single protoplast subjected to 
ATM (see FIG. 8). Thus, daughter cultures of the original 
clone continued to overproduce activity in the screen. Some 
of these cultures Were regenerated into intact plants Which set 
seed. Extracts of the seed Were screened, and these continued 
to shoW greater activity in the screen than Wild-type N 
Zabacum seed. Plants Were groWn from this seed and leaf 
punch extracts from young seedlings shoWed greater activity 
in the screen than leaf punches from Wild-type seedlings. Leaf 
protoplasts from these plants Were groWn to the microcallus 
level and these microcalli Were found to be still overproduc 
ing activity relative to Wild-type cultures. 
The only situation in Which clone 1402 Was not found to be 
an overproducer relative to Wild-type Was in leaf punches 
from relatively mature plants. At this stage nicotine produc 
tion is rising rapidly in the Wild-type plants and this might 
Well eliminate the difference from the clonal plant. Addition 
ally, assessing the production of nicotine-like alkaloids in leaf 
punches from mature plants is subject to the Heisenberg 
principle because leaf damage massively increases the syn 
thesis and transport of nicotine. Our failure to observe a 
difference in the screen betWeen clone 1402 and Wild-type 
plants at the mature plant stage illustrates the potential di?i 
culties of evaluating differences in natural products in a popu 
lation of mutant intact plants. Metabolic pro?ling of the 
plants at this stage by GC/MS also did not reveal any differ 
ences in alkaloid material (see FIG. 7). 
Since 1402 consistently overproduces activity in the epi 
batidine displacement screen it Would seem to be a simple 
matter to establish What compound or compounds it is pro 
ducing that account for this activity. Unfortunately this is 
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more dif?cult than Would be expected. The problem is one of 
sensitivity and quantitation. The screen is semi-quantitative at 
best, but it is extraordinarily sensitive, being easily able to 
respond to picogram quantities of nicotine in a culture extract. 
Chemical analytical methods such as GC/MS (as in FIG. 7) 
are about l000>< less sensitive, and to date We have not accu 
mulated enough clonal culture material to be able to analyZe 
extracts quantitatively for knoWn and novel nicotine-like 
alkaloids. We have therefore used a combination of pharma 
cological analysis and separation techniques to investigate 
extracts of clone 1402 in comparison With extracts from Wild 
type microcallus. 
Nicotine is the most pharmacologically alkaloid in the 
intact plant, and this alkaloid can be detected by GC/MS in 
extracts from Wild-type cultures. Therefore, the most likely 
reason for the increased activity in extracts from clonal cul 
ture #1402 is that this is producing more nicotine than the 
Wild-type cultures. This does not appear to be the case. Thus, 
this clonal culture Was identi?ed on the basis of greater dis 
placement of epibatidine, a ligand With relative selectivity for 
alpha3-containing nicAChRs on brain membranes. In con 
trast, nicotine, and the partial agonist cytisine, have a higher 
af?nity for nicAChRs on brain containing alpha4 subunits. If 
the active principle in clone #1402 is nicotine it should dis 
place [3H]nicotine or [3H]cytisine from brain membranes to 
a greater extent than it displaces [3H]epibatidine. In fact the 
reverse is the caseithe same extract from 1402 that is an 
order of magnitude more effective at displacing epibatidine is 
no more effective than that from Wild-type cultures in dis 
placing nicotine or (see FIG. 9). This suggests that Whatever 
is responsible for the activity has a greater af?nity for alpha3 
containing nicAChRs, and this is inconsistent With this being 
nicotine or probably any of the other major alkaloids in 
tobacco (see beloW). 
FIG. 9 also shoWs another important pharmacological 
characteristic of the culture extracts. The dilution/response 
relation in the screens is very similar to that for pure nicotine. 
This suggests that the displacement of the respective radioli 
gands is by direct competition for the binding site, rather than 
by indirect or allosteric effects. This type of interaction sug 
gests an alkaloid that is a structural relative of nicotine rather 
than a totally different type of compound. For example We 
knoW that the cultures produce polyamines (see beloW) and 
these compounds can affect nicAChR binding allosterically. 
The suggestion that the compound in clone 1402 is structur 
ally similar to the knoWn tobacco alkaloids is supported by 
results from serial fractionation of the extracts from #1402 
and Wild-type cultures. We compared these fractions for 
activity in the radioligand binding screens and also compared 
the recovery in each phase With that of standards representing 
the major alkaloids present in N Zabacum. In general, the 
activity in extracts from #1402 shoWed a similar distribution 
to that from Wild-type cultures and to that of alkaloid stan 
dards (not shoWn here). 
Taken together, all this data is consistent With the produc 
tion, by clone 1402, of an alkaloidal compound (or com 
pounds) With structural similarity to nicotine, but Which bind 
With high af?nity to nicAChRs containing alpha3 subunits. 
Since none of the major alkaloids in the plant have exactly 
these characteristics, then We appear to have produced a 
stable mutation that causes “overproduction” either of a com 
pound that is not normally found in the plant, or one that is 
normally produced in very small amounts. This ?nding, and 
the procedure We used to come to this conclusion, has some 
implications for drug discovery. Speci?cally, if the main pur 
pose of this technology is to discover clones that are produc 
ing active compounds other than the major active principle in 
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the plant, it is a simple matter to use differential activity in tWo 
related screens to do this. Those clones that are simply over 
producing the “Wild-type compound” Will produce a charac 
teristic ratio of activity in the tWo screens. Those that are 
producing some product With novel properties Will usually 
produce a ratio of activity that differs from this. 
Since the T-DNA that has been inserted into the N Zabacum 
genome during the ATM procedure is “tagged” With bacterial 
DNA, it is a relatively simple method to rescue this material 
together With sections of the plant genes surrounding it. HoW 
ever, this does not guarantee that the piece of plant DNA that 
is obtained is responsible for the altered chemical phenotype. 
Thus the in?uence of the viral enhancer sequences inserted 
into the genome extends for as much as 10-Kb pairs in each 
direction from the insert, and it may be any gene Within this 
range that is of value for natural product synthesis. Another 
potential problem is that there may be more than one insert. 
The important activation may be in one of these rather than 
the other or, possibly, it could require both. Fortunately clone 
#1402 has only one T-DNA insert and We have used plasmid 
rescue techniques to obtain genomic plant DNA from the 
region of this insert. To date We have isolated approximately 
1.8-Kb pairs of this material (see FIG. 10), Which is probably 
of insuf?cient length to encode a complete gene. HoWever, 
the sequence analysis indicates very strongly suggests that 
the cloned genomic DNA does indeed encode intact genes in 
that the deduced amino acid sequence from this region reveals 
some homology With expressed genes When compared With 
existing gene databanks. In particular, there is homology With 
expressed sequence tags obtained from a soybean roots that 
represents a gene of unknoWn function (FIG. 10). Since the 
nicotine alkaloids are synthesized in roots, this at least shoWs 
the expected tissue speci?city. 
Those skilled in the art Will recogniZe, or be able to ascer 
tain using no more than routine experimentation, many 
equivalents to the speci?c embodiments of the invention spe 
ci?cally described herein. Such equivalents are intended to be 
encompassed in the scope of the folloWing claims. 
We claim: 
1. A high throughput screening method for detecting a 
metabolite of interest in a plant comprising; 
a) causing integration of a T-DNA sequence encoding at 
least one transcription enhancer and at least one select 
able marker gene in a plurality of plant protoplasts; 
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b) groWing said protoplasts to the stage of callus culture 
under selective conditions; 
c) removing a tissue sample from the resulting individual 
callus cultures in such a manner so as to retain viability 
of said callus cultures; 
d) screening for the metabolite of interest in the tissue 
sample in the event that the metabolite of interest is 
present via a radiolabeled ligand binding assay, Wherein 
the radiolabeled ligand binds nicotinic acetyleholine 
receptors. 
2. The method of claim 1, Wherein the metabolite of inter 
est is detected. 
3. The method of claim 2, Which further comprises the step 
of propagating at least one daughter culture from the callus 
culture in Which the metabolite of interest Was detected. 
4. The method of claim 1, Wherein said plant is a tobacco 
plant. 
5. The method of claim 1, Wherein said transcription 
enhancer is a plant viral transcription enhancer sequence. 
6. A method of claim 5, Wherein said transcription 
enhancer is an A grobaclerium Zumefaciens enhancer 
sequence. 
7. The method of claim 1, Wherein said radiolabeled ligand 
is a nicotinic acetylcholine agonist. 
8. The method of claim 1 Wherein said radiolabeled ligand 
is a nicotinic acetylcholine antagonist. 
9. The method of claim 4, Wherein said metabolite of 
interest is detected With 3H-epibatidinc. 
10. The method of claim 1 Wherein the tissue sample 
removed in step (c) is used to establish a library of trans 
formed callus cultures. 
11. The method of claim 10 Wherein the transformed callus 
cultures in the library that test positive for the metabolite of 
interest are rescreened at least one time for the presence of the 
metabolite of interest by removing a tissue sample from each 
of said callus cultures in such a manner so as to retain viability 
of the callus cultures. 
12. The method of claim 10 further comprising the step of 
isolating a gene involved in the production of the metabolite 
of interest from a callus culture of the library that tests posi 
tive for the metabolite of interest after at least one rescreening 
for said metabolite of interest. 
